Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners. The firm also raised its price target on the stock to $48 from $38. Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday The rating update came after the ESMO presentation of the Phase 3 STELLAR-303 trial that evaluated zanzalintinib plus atezolizumab versus regorafenib in 3L non MSI-high metastatic colorectal cance ...

By Georgina McCartney HOUSTON (Reuters) -Oil prices slipped about 2% on Tuesday and were on track for a third straight day of declines as investors considered the impact of U.S. sanctions against Russia's two biggest oil companies on global supply, along with a potential OPEC+ plan to raise output. Brent crude futures were down $1.36, or 2.1%, to $64.26 a barrel at 11:48 a.m. EDT (1548 GMT). U.S. West Texas Intermediate crude futures were down $1.29, or 2%, at $60.02. Brent and WTI last week registered ...

Core Insights - Argenx SE (NASDAQ:ARGX) is recognized as a highly profitable biotech stock, with analysts maintaining a positive outlook and setting high price targets [1][2] Financial Performance - The company reported impressive Q2 revenues for its medication Vyvgart, achieving a 20% quarter-over-quarter growth, which exceeded expectations [2] - Q3 revenue is projected to surpass $1 billion, driven by the drug's expansion into new geographical regions and the anticipated approval of a prefilled syringe [3] Analyst Ratings - Citi analyst Samantha Semenkow maintained a Buy rating on Argenx SE and set a price target of $1,041 [1] - Bank of America Securities analyst Tazeen Ahmad also reiterated a Buy rating, increasing the price target from $887 to $942 [1][2] Market Segments - Argenx SE operates through four segments: the United States, Japan, EMEA, and China, focusing on treatments for severe autoimmune diseases [3]

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its innovativ ...

Core Viewpoint - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a highly profitable biotech stock with strong growth potential and a solid market position, supported by positive analyst ratings and price targets from major financial institutions [1][2][3]. Group 1: Analyst Ratings and Price Targets - Wells Fargo maintained a Buy rating on BioMarin with a price target of $90 as of October 21 [1]. - Morgan Stanley analyst Sean Laaman also assigned a Buy rating with a price target of $104 on October 19 [2]. Group 2: Growth Potential and Market Position - BioMarin has considerable growth potential, driven by the international expansion of its product Voxzogo, which has led to significant revenue growth [3]. - The company has a competitive market position due to its strategic focus on building a solid patient base with low switch rates, particularly among younger age cohorts [4]. Group 3: Product Pipeline - BioMarin develops therapies for serious medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [5]. - Promising treatments in the pipeline, such as BMN 333 and BMN 351, represent future growth catalysts for the company [4].

Core Insights - Apple achieved a market value of over $4 trillion for the first time, becoming the third Big Tech company to reach this milestone, following Nvidia and Microsoft [1][8] - The stock price remained stable at $269 after reaching an all-time high, with shares gaining approximately 13% since the launch of new iPhone models on September 9, marking a significant recovery for the year [1][3] iPhone Performance - The iPhone constitutes over half of Apple's profit and revenue, and increased sales drive customer engagement within Apple's ecosystem [3] - The latest iPhone models, including the iPhone 17 and iPhone Air, have attracted customers globally, with early sales of the iPhone 17 outperforming its predecessor by 14% in key markets like the US and China [4][5][7] Market Expectations - Analysts predict that strong demand for the new iPhones will enable Apple to exceed market expectations for the quarter ending in September and provide positive forecasts for the December quarter [7] - Apple's shares are currently trading at 33.2 times projected earnings for the next 12 months, which is higher than the Nasdaq 100's 27.42 [17] Competitive Landscape - Earlier in the year, Apple faced challenges due to competition in China and uncertainties regarding high US tariffs on Asian manufacturing hubs [4] - The iPhone Air's design is seen as a competitive advantage against rivals like Samsung Electronics [5] AI Strategy Concerns - Apple's cautious approach to artificial intelligence has raised concerns about its potential to miss out on significant growth opportunities in the industry [9][13] - Reports indicate that Apple is losing senior AI executives to competitors like Meta, and the rollout of its AI initiatives has been slower than expected [9][12]

Gold extended declines on Tuesday to a three-week low as optimism over a US-China trade deal continued to put pressure on the safe-haven asset. Bullion futures dropped more than 1% to hover near $3,970 per troy ounce, while gold for immediate delivery fell to around $3,930 ahead of a highly anticipated meeting on Thursday between President Trump and China’s leader Xi Jinping. The move extended declines in the precious metal, which were sparked last Tuesday with the biggest drop in more than a decade. “I ...

Neils ChristensenNeils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada. He has worked exclusively within the financial sector since 2007, when he started with the Canadian Economic Press. Neils can be contacted at: 1 866 925 4826 ext. 1526 nchristensen at kitco.com @Neils_cShareDisclaimer: The views expressed ...

BlackRock CEO Larry Fink has declared that investors are rushing into crypto and precious metals such as gold as "assets of fear," driven by mounting concerns over spiraling government debt worldwide. "Owning crypto assets or gold are assets of fear," Fink said during his appearance at the Future Investment Initiative conference in Riyadh, according to a Bloomberg report. "You own these assets because you're frightened of the debasement of your assets. You're worried about your financial security. You're ...

Key Takeaways Dominion Energy's Q3 2025 results will benefit from rising demand in the Virginia and South Carolina areasQ3 earnings may benefit from new rates, strong demand and clean energy generation gains.Higher financing costs, share dilution and lower nuclear PTC may limit overall earnings growth.Dominion Energy (D) is scheduled to release third-quarter 2025 results on Oct. 31, before market open. The company delivered an earnings surprise of 8.7% in the last reported quarter. Let us discuss the factor ...